Clinical Trials Browser

Phase 1/2 × Completed × nazartinib × Clear all

NCT02108964 2024-12-11

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Phase 1/2 Completed

225 enrolled 31 charts

Advanced Non-small Cell Lung Cancer